Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status

Character	Newly-diagnosed (n = 134)		Recently – diagnosed (n=262)						Whole sample (n = 396)
	Newly-diagnosed (n = 134)		Non-chemo (n = 86)		Chemo (n = 176)		Total (n = 262)		Whole sample (n = 396)
	Mean ± SEM		Mean ± SEM		Mean ± SEM		Mean ± SEM		Mean ± SEM
SBP (mmHg)	119.1	1.1^a	119.5	1.2^a	123.0	0.9^b	121.9	0.8^a	120.9	0.6
DBP (mmHg)	78.4	1.0^a	78.0	0.8^a	79.6	0.7^a	79.1	0.5^a	78.8	0.5
HDL-C(mg/dl)	47.8	0.8^a	42.9	1.0^b	47.6	0.7^a	45.6	0.6^b	46.4	0.5
LDL-C (mg/dl)	126.9	9.0^a	141.0	3.4^a	128.8	2.8^a	132.8	2.2^a	130.8	3.4
TG (mg/dl)	195.7	5.8^a	221.8	8.9^b	205.9	5.6^b	211.1	4.7^b	205.9	3.7

[i] 1. Values are given as mean ± SEM.

[ii] 2. Values in rows with different superscripts are significantly different (p < 0.05).

[iii] 3. Abbreviations and definitions: newly diagnosed: newly-diagnosed: breast cancer patients who are not exposed to any type of interventions; recently-diagnosed: breast cancer patients within 3 months of diagnosis who are either exposed (chemo) or not exposed (non-chemo) to chemical therapy; SEM: stander error of mean; SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol; TG: triglycerides; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol.

Table 4.2

Prevalence of the dyslipidemia risk factors and hypertension according to treatment exposure^{(1, 2, 3, 4)}

Variables	Cut-off points	Newly diagnosed (n = 134)		Recently – diagnosed (n = 262)						Whole sample (n = 396)
		Newly diagnosed (n = 134)		Non-chemo (n = 86)		Chemo (n = 176)		Total (n = 262)		Whole sample (n = 396)
		n	%	n	%	n	%	n	%	n	%
SBP (mmHg)	> 130	14	10.4^a	8	9.3^a	34	19.3^b	42	16.0^b	56	14.1
DBP (mmHg)	> 85	24	17.9^a	11	12.8^a	38	21.6^a	49	18.7^a	73	18.4
Overt hypertension^*		31	23.1	10	11.6	49	27.8	59	22.5	90	22.7
HDL-C (mg/dl)	< 50	82	61.2^a	70	81.4^b	112	63.6^a	182	69.5^b	264	66.7
TG (mg/dl)	> 150	102	76.1^a	73	84.9^b	143	81.2^b	216	82.4^b	318	80.3
TC (mg/dl)	> 200	90	67.2^a	75	87.2^b	137	77.8^b	212	80.9^b	302	76.3
Overt dyslipidemia^*		7	5.2	2	2.3	10	5.7	12	4.6	19	4.8

1. Values given as number of patients (n) and their percentages out of (N).

2. Values in rows with different superscripts are significantly different (p < 0.05).

3. Cut-off points were based on Albertiet al., 2009 definition of metabolic abnormalities.^[15]

4. Abbreviations and definitions: newly-diagnosed: breast cancer patients who are not exposed to any type of interventions; recently-diagnosed: breast cancer patients within 3 months of diagnosis who are either exposed (chemo) or not exposed (non-chemo) to chemical therapy; SEM: stander error of mean; SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol; TG: triglycerides; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol.

* The study patients who are on anti-hypertensive or lipid lowering agents.

Table 4.3

Prevalence of dyslipidemia risk factors and hypertension in pre and postmenopause according to treatment exposure^{(1, 2, 3, 4, 5)}

Metabolic risk	Newly-diagnosed (N = 134)				Recently-diagnosed (N = 262)				Whole sample (N = 396)
	Premeno-pause (N = 80)		Postmeno-pause (N = 54)		Premeno-pause (N = 149)		Postmeno-pause (N = 113)		Premeno-pause (N = 229)		Postmeno-pause (N = 167)
	n	%	n	%	n	%	n	%	n	%	n	%
*SBP^ (mmHg)**	6	4.5	8	6.0	13	5.0	29	11.1	19	4.8	37	9.3
*DBP^ (mmHg)**	8	6.0	16	11.9	20	7.6	29	11.1	28	7.1	45	11.4
*HDL^ (mg/dl)**	48	35.8	34	25.4	104	39.7	78	29.9	152	38.4	112	28.3
*TG^ (mg/dl)**	56	41.8	46	34.3	116	44.3	100	38.3	172	43.4	146	36.9

[i] 1. Documented international cut-off points: Alberti et al.[15]

[ii] 2. Values are given as number of patients (n) and their percentages out of (N).

[iii] 3. (^*) Significantly (p < 0.05) different between pre and postmenopausal women for each treatment exposure and whole sample.

[iv] 4. Cross differences between treatment exposure groups were not significant (p > 0.05).

[v] 5. Abbreviations and definitions: newly diagnosed: breast cancer patients who are not exposed to any type of interventions; recently diagnosed: breast cancer patients within 3 months of diagnosis who are either exposed (chemo) or not exposed (non-chemo) to chemical therapy; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglycerides; HDL-C: high density lipoprotein.

Table 4.4

Dyslipidemia and hypertension characteristic in pre and postmenopause women according to treatment exposure^{(1, 2, 3, 4, 5)}

Metabolic risks	Newly-diagnosed (N = 134)				Recently-diagnosed (N = 262)				Whole sample (N = 396)
	Premeno-pause (N = 80)		Postmeno-pause (N = 54)		Premeno-pause (N = 149)		Postmeno-pause (N = 113)		Premeno-pause (N = 229)		Postmeno-pause (N = 167)
	Mean ± SEM		Mean ± SEM		Mean ± SEM		Mean ± SEM		Mean ± SEM		Mean ± SEM
*SBP^(mmHg)**	117.1	1.5	121.1	1.7^a	118.5	0.9	136.2	1.2^b	118.0	0.8	129.3	1.0
DBP(mmHg)	76.6	1.4	80.9	1.1	78.3	0.6	80.2	1.0	78.0	0.6	80.0	0.7
HDL-C(mg/dl)	47.9	0.9	47.7	1.6	44.8	0.8	46.7	0.9	46.0	0.6	47.0	0.8
*TG^ (mg/dl)**	182.5	6.9	215.3	9.6	201.7	6.1	223.5	7.4	195.0	4.7	221.0	5.9

[i] 1. Documented international cut-off points: Alberti, et al.^[15]

[ii] 2. Values are given as mean ± SEM.

[iii] 3. (^*) Significant differences (p < 0.05) between pre and postmenopausal women for treatment exposure groups and whole sample.

[iv] 4. Values in rows with different superscripts are significantly different among treatment exposure groups (p < 0.05). None of other values in rows show significant differences (p > 0.05).

Table 4.5

Age-controlled partial correlation coefficients of dyslipidemia risk factors and hypertension with obesity indices and selected biomarkers in the study sample^(1–2)

Metabolic risks	BMI	WC	WHpR	WHtR	leptin	HOMA	C-peptide
SBR(mmHg)	0.04	0.08	0.12	0.08	0.10	0.14^**	0.03
DBR (mmHg)	0.01	0.17^***	0.15^**	0.13^*	0.08	0.10^*	−0.02
HDL-C(mg/dl)	−0.11^*	−0.11^*	−0.09	−0.13^**	−0.02	0.02	0.03
TG (mg/dl)	0.05	0.16^***	0.08	0.15^**	−0.11^*	0.03	0.02

{ label (or @symbol) needed for fn[@id='j_fco-2019-0018_table-fn_004'] } 1. ^*: (p < 0.05);

** : (p < 0.01);

*** : (p < 0.001).

2. Abbreviations and definitions: newly diagnose: BMI: body mass index; WC: waist circumferences cm; WHtR: waist to height ratio; WHpR: waist to hip ratio; HOMA: homeostasis model assessment according to the following formulas[14]: Log (HOMA) as log [FBG (mmol/L) × FBI (μU/ml)/22.^[15]

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/fco-2019-0018 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 39 - 46

Submitted on: Jun 30, 2018

Accepted on: Apr 29, 2019

Published on: May 2, 2021

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Keywords:

Related subjects:

Haematology, oncology

© 2021 Safaa A. Al-Zeidaneen, Mousa N. Ahmad, Ali D. Al-Ebous, Rawan MohD Al Saudi, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 12 (2021): Issue 1 (May 2021)